



PB 56 of 2025

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 5)

National Health Act 1953

I, REBECCA RICHARDSON, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under subsection 84AAA(2) of the *National Health Act 1953*.

Dated 29 May 2025

REBECCA RICHARDSON

Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division

Contents

1	Name.....	1
2	Commencement.....	1
3	Authority	1
4	Schedules	1
Schedule 1—Amendments		2
<i>National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).</i>		<i>2</i>

1 Name

- (1) This instrument is the *National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2025 (No. 5)*.
- (2) This instrument may also be cited as PB 56 of 2025.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. The whole of this instrument	1 June 2025	1 June 2025

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 84AAA(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

[1] Schedule 1, entry for Evolocumab

omit:

Injection 420 mg in 3.5 mL single use pre-filled cartridge	20	1	5
--	----	---	---

[2] Schedule 1, entry for Prazosin in the form Tablet 1 mg (as hydrochloride)

omit from the column headed “Listed drug”: **Prazosin**

[3] Schedule 2, entry for Mesalazine

insert as first entry:

Enemas 1 g in 100 mL, 7	50	8	5
Enemas 2 g in 60 mL, 7	50	8	5
Enemas 4 g in 60 mL, 7	50	8	5
Rectal foam 1 g per applicatorful, 14 applications, aerosol 80 g	50	8	5

[4] Schedule 2, after entry for Mesalazine in the form Sachet containing prolonged release granules, 4 g per sachet

insert:

Suppository (moulded) 1 g	50	60	5
Suppository 1 g	50	56	5

[5] Schedule 2, entry for Prazosin in the form Tablet 1 mg (as hydrochloride)

omit from the column headed “Listed drug”: **Prazosin**

[6] Schedule 2, after entry for Tiotropium in the form Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations)

insert:

Solution for oral inhalation 2.5 micrograms (as bromide monohydrate) per actuation (60 actuations), pack of 2	50	1	5
---	----	---	---

[7] Schedule 2, after entry for Tiotropium with olodaterol

insert:

Solution for oral inhalation containing tiotropium 2.5 micrograms (as bromide monohydrate) with olodaterol 2.5 micrograms (as hydrochloride) per dose, 60 doses, pack of 2	50	1	5
--	----	---	---